but less with valsartan than with amlodipine, particularly during the first 6 months. The two groups did not differ in the primary composite endpoint of adverse cardiovascular events. However ...

OBJECTIVE: To examine in patients treated with a regimen including single-pill combinations (SPCs) of amlodipine/valsartan (1) blood pressure (BP) reduction and control, total cardiovascular risk ...

The US Court of Appeals for the Federal Circuit has reversed the New Jersey District Court's dismissal of Pfizer's patent infringement action against Dr Reddy's Laboratories' generic version of ...